Skip Content
You are currently on the new version of our website. Access the old version .
  • Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Current Oncology, Volume 19, Issue 1

2012 February - 16 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (16)

  • Article
  • Open Access
7 Citations
809 Views
9 Pages

1 February 2012

Background: Cancer Care Ontario’s Program in Evidence-Based Care (pebc) was formalized in 1997 to produce clinical practice guidelines for cancer management for the Province of Ontario. At the time, the gap between guideline development and implement...

  • Article
  • Open Access
33 Citations
1,906 Views
3 Pages

Major Histocompatibility Complex Class I and Tumour Immuno-Evasion: How to Fool T Cells and Natural Killer Cells at One Time

  • D. Fruci,
  • M. Benevolo,
  • L. Cifaldi,
  • S. Lorenzi,
  • E. Lo Monaco,
  • E. Tremante and
  • P. Giacomini

1 February 2012

Cytotoxic T lymphocytes (ctls) and natural killer (nk) cells lyse tumours expressing and lacking, respectively, properly conformed class i molecules of the major histocompatibility complex [mhc-i (Figure 1)] [...]

  • Article
  • Open Access
3 Citations
961 Views
5 Pages

1 February 2012

Erlotinib—an oral tyrosine kinase inhibitor (tki) of the epidermal growth factor receptor (egfr)—has commonly been used as a therapeutic option in metastatic non-small-cell lung cancer (nsclc) patients in the second- or third-line treatment setting....

  • Article
  • Open Access
16 Citations
1,533 Views
8 Pages

1 February 2012

The alpha-fetoprotein (afp) receptor (recaf) is an oncofetal antigen found in most types of cancer. Using a competitive radioimmunoassay, we measured the concentration of serum recaf in three sets of samples. Set 1 was blind and consisted of 119 nor...

  • Article
  • Open Access
130 Citations
2,704 Views
12 Pages

1 February 2012

Background: Lung cancer leads cancer-related mortality in the world. The objective of the present systematic review was to compare fine-needle aspiration biopsy (FNAB) with core-needle biopsy (CNB) for diagnostic characteristics and yields for diagno...

  • Article
  • Open Access
73 Citations
1,826 Views
8 Pages

Phase I Study of the Plk1 Inhibitor BI 2536 Administered Intravenously on Three Consecutive Days in Advanced Solid Tumours

  • A. Frost,
  • K. Mross,
  • S. Steinbild,
  • S. Hedbom,
  • C. Unger,
  • R. Kaiser,
  • D. Trommeshauser and
  • G. Munzert

1 February 2012

Background: This open-label phase i study with an accelerated titration design was performed to determine the maximum tolerated dose of BI 2536, a potent, highly selective small-molecule polo-like kinase 1 (Plk1) inhibitor. Methods: Patients with adv...

  • Case Report
  • Open Access
24 Citations
1,173 Views
6 Pages

Medullary Thyroid Cancer and Pseudocirrhosis: Case Report and Literature Review

  • B.L. Harry,
  • M.L. Smith,
  • J.R. Burton,
  • A. Dasari,
  • S.G. Eckhardt and
  • J.R. Diamond

1 February 2012

Pseudocirrhosis is a rare form of liver disease that can cause clinical symptoms and radiographic signs of cirrhosis; however, its histologic features suggest a distinct pathologic process. In the setting of cancer, hepatic metastases and systemic ch...

  • Article
  • Open Access
42 Citations
1,319 Views
7 Pages

1 February 2012

Purpose: Platinum-based regimens represent the standard first-line treatment for non-small-cell lung cancer (SNCLC). However, newer data have established a role for pemetrexed in the treatment of this disease. Such data suggest that histology represe...

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Curr. Oncol. - ISSN 1718-7729